Roche takes on Loxo, Bayer in gene-defined cancer class [Reuters (UK)]
LOXO ONCOLOGY (LOXO)
Last loxo oncology earnings: 11/8 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.loxooncology.com
Company Research
Source: Reuters
Roche takes on Loxo, Bayer in gene-defined cancer class | Reuters 5 Min Read MUNICH (Reuters) - Roche’s ( ROG.S ) entrectinib cancer pill was shown to shrink tumours in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer ( BAYGn.DE ) and Loxo Oncology ( LOXO.O ) in a new targeted treatment area. The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumour types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany’s Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. Traditionally, oncologists have made treatment decisions based on where in the body a tumour started, increasingly helped by the growing knowledge of cancer’s complex gen
Show less
Read more
Impact Snapshot
Event Time:
LOXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LOXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LOXO alerts
High impacting LOXO ONCOLOGY news events
Weekly update
A roundup of the hottest topics